INTELLIA THERAPEUTICS INC(NASDAQ:NTLA) stock News

NTLA Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Benzinga - Mentions: ALNY

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

4 days ago - By: Intellia Therapeutics, Inc.

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

7 days ago - By: Intellia Therapeutics, Inc.

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

10 days ago - By: Benzinga - Mentions: SNDK DK FDX UPS ...

Tesla To Rally More Than 31%? Here Are 10 Top Analyst Forecasts For Friday

10 days ago - By: Stocktwits - Mentions: IWMW ESGV

Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright – Check Out The Details

2 months ago - By: The Motley Fool

Intellia (NTLA) Q2 Revenue Jumps 106%

11 days ago - By: Intellia Therapeutics, Inc.

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

19 days ago - By: The Motley Fool - Mentions: CRSP VRTX ARKK

Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%

19 days ago - By: Zacks Investment Research - Mentions: XENE

Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report?

a month ago - By: Zacks Investment Research - Mentions: ORCL CBRE FAST TMO ...

Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus

a month ago - By: Zacks Investment Research - Mentions: VRTX BEAM CRSP

Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?

a month ago - By: Zacks Investment Research - Mentions: VRTX BEAM CRSP

CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock

a month ago - By: Yahoo Finance

Cathie Wood Is Betting Big on Intellia Therapeutics. Should You Buy NTLA Stock Here?

2 months ago - By: Zacks Investment Research - Mentions: VRTX BEAM CRSP

Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?

2 months ago - By: Zacks Investment Research - Mentions: SBUX GS JNJ INTU ...

Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus

2 months ago - By: Zacks Investment Research - Mentions: REGN CRMD IMCR

Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

2 months ago - By: Zacks Investment Research - Mentions: PRQR

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates

2 months ago - By: Intellia Therapeutics, Inc.

Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress

2 months ago - By: Intellia Therapeutics, Inc.

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Bragar Eagel & Squire

INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

2 months ago - By: Intellia Therapeutics, Inc.

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

3 months ago - By: Yahoo Finance - Mentions: AVGO BABA MRNA

The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.

3 months ago - By: Intellia Therapeutics, Inc.

INTELLIA THERAPEUTICS INC (NTLA) Stock News

NTLA Latest News, Press Relases and Analysis